Ratings by Piper Sandler (David Amsellem)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/4/2026 | Teva Pharma | TEVA | Maintain | Overweight (N/A) |
|
Details | ||
| 2/27/2026 | Pelthos Therapeutics | PTHS | New Coverage | Overweight (N/A) |
23.00 (23.12) |
0.52% | Details | |
| 2/23/2026 | Bristol-Myers Squibb Co. | BMY | Maintain | Overweight (N/A) |
|
Details | ||
| 2/18/2026 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/18/2026 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 2/9/2026 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 1/28/2026 | Viatris | VTRS | Maintain | Neutral (N/A) |
|
Details | ||
| 1/28/2026 | Bristol-Myers Squibb Co. | BMY | Maintain | Overweight (N/A) |
|
Details | ||
| 1/16/2026 | Axsome Therapeutics | AXSM | Maintain | Overweight (N/A) |
|
Details | ||
| 1/9/2026 | Fennec Pharmaceuticals Inc. | FENC | New Coverage | Overweight (N/A) |
7.60 (7.70) |
1.32% | Details | |
| 12/22/2025 | Teva Pharma | TEVA | Maintain | Overweight (N/A) |
|
Details | ||
| 12/10/2025 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 11/25/2025 | Esperion Therapeutics | ESPR | New Coverage | Overweight (N/A) |
3.08 (2.73) |
-11.36% | Details | |
| 11/21/2025 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 11/17/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Overweight (N/A) |
|
Details | ||
| 11/14/2025 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/10/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Overweight (N/A) |
|
Details | ||
| 11/7/2025 | Xeris Pharmaceuticals | XERS | Maintain | Neutral (N/A) |
|
Details | ||
| 11/7/2025 | Aquestive Therapeutics | AQST | Maintain | Overweight (N/A) |
|
Details | ||
| 11/5/2025 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 11/5/2025 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/31/2025 | Indivior | INDV | Maintain | (N/A) |
|
Details | ||
| 10/31/2025 | Amneal Pharmaceuticals | AMRX | Maintain | (N/A) |
|
Details | ||
| 10/29/2025 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/27/2025 | Organon & Co. | OGN | Downgrade | Underweight (Overweight) |
9.16 (6.56) |
-28.38% | Details | |
| 10/23/2025 | Alkermes | ALKS | Maintain | Overweight (N/A) |
|
Details | ||
| 10/22/2025 | Avadel Pharmaceuticals | AVDL | Downgrade | Neutral (Overweight) |
17.87 (21.64) |
21.1% | Details | |
| 10/17/2025 | Supernus Pharmaceuticals | SUPN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/10/2025 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 10/9/2025 | Supernus Pharmaceuticals | SUPN | Upgrade | Overweight (Neutral) |
48.07 (53.87) |
12.07% | Details | |
| 10/6/2025 | Alkermes | ALKS | Maintain | Overweight (N/A) |
|
Details | ||
| 9/17/2025 | Axsome Therapeutics | AXSM | Maintain | Overweight (N/A) |
|
Details | ||
| 9/15/2025 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 9/12/2025 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 8/29/2025 | Supernus Pharmaceuticals | SUPN | Maintain | Neutral (N/A) |
|
Details | ||
| 8/28/2025 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/27/2025 | Indivior | INDV | Maintain | Overweight (N/A) |
|
Details | ||
| 8/26/2025 | Aquestive Therapeutics | AQST | Maintain | Overweight (N/A) |
|
Details | ||
| 8/25/2025 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/18/2025 | Alkermes | ALKS | Maintain | Overweight (N/A) |
|
Details | ||
| 8/14/2025 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 8/12/2025 | Abbvie | ABBV | New Coverage | Overweight (N/A) |
198.05 (230.11) |
16.19% | Details | |
| 8/8/2025 | Amphastar Pharmaceuticals | AMPH | Maintain | Neutral (N/A) |
|
Details | ||
| 8/1/2025 | Corcept Therapeutics | CORT | Maintain | Overweight (N/A) |
|
Details | ||
| 7/31/2025 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/29/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Overweight (N/A) |
|
Details | ||
| 7/29/2025 | Teva Pharma | TEVA | Maintain | Overweight (N/A) |
|
Details | ||
| 7/11/2025 | Corcept Therapeutics | CORT | Maintain | Overweight (N/A) |
|
Details | ||
| 7/1/2025 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 6/24/2025 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 6/17/2025 | Supernus Pharmaceuticals | SUPN | Maintain | Neutral (N/A) |
|
Details | ||
| 6/17/2025 | Sage Therapeutics | SAGE | Downgrade | Neutral (Overweight) |
6.70 (8.68) |
29.55% | Details | |
| 6/10/2025 | Axsome Therapeutics | AXSM | Maintain | Overweight (N/A) |
|
Details | ||
| 5/16/2025 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/9/2025 | Collegium Pharmaceutical | COLL | Maintain | Neutral (N/A) |
|
Details | ||
| 5/6/2025 | Corcept Therapeutics | CORT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/6/2025 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/24/2025 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/22/2025 | Bristol-Myers Squibb Co. | BMY | New Coverage | Overweight (N/A) |
49.23 (60.29) |
22.47% | Details | |
| 4/14/2025 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/4/2025 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/3/2025 | Corcept Therapeutics | CORT | Maintain | Overweight (N/A) |
|
Details | ||
| 3/26/2025 | Axsome Therapeutics | AXSM | Maintain | Overweight (N/A) |
|
Details | ||
| 3/25/2025 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/21/2025 | Amphastar Pharmaceuticals | AMPH | Maintain | Neutral (N/A) |
|
Details | ||
| 3/20/2025 | Optinose | OPTN | Downgrade | Neutral (Overweight) |
6.00 (9.60) |
60% | Details | |
| 3/11/2025 | Axsome Therapeutics | AXSM | Maintain | Overweight (N/A) |
|
Details | ||
| 3/7/2025 | Xeris Pharmaceuticals | XERS | Maintain | Neutral (N/A) |
|
Details | ||
| 3/6/2025 | Indivior | INDV | Maintain | Overweight (N/A) |
|
Details | ||
| 3/5/2025 | Viatris | VTRS | Maintain | Neutral (N/A) |
|
Details | ||
| 2/27/2025 | Corcept Therapeutics | CORT | Maintain | Overweight (N/A) |
|
Details | ||
| 2/26/2025 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 2/18/2025 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 2/10/2025 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/4/2025 | Collegium Pharmaceutical | COLL | Maintain | Neutral (N/A) |
|
Details | ||
| 2/4/2025 | Amphastar Pharmaceuticals | AMPH | Downgrade | Neutral (Overweight) |
34.87 (19.34) |
-44.54% | Details | |
| 1/17/2025 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 1/17/2025 | Teva Pharma | TEVA | Maintain | Overweight (N/A) |
|
Details | ||
| 1/13/2025 | Intra-Cellular Therapies | ITCI | Downgrade | Neutral (Overweight) |
94.87 (131.87) |
39% | Details | |
| 1/10/2025 | Avadel Pharmaceuticals | AVDL | Maintain | Overweight (N/A) |
|
Details | ||
| 1/8/2025 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/2/2025 | Sage Therapeutics | SAGE | Maintain | Overweight (N/A) |
|
Details | ||
| 1/2/2025 | Amgen | AMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 1/1/2025 | Biogen | BIIB | Downgrade | Neutral (Overweight) |
152.92 (184.87) |
20.89% | Details | |
| 12/23/2024 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/12/2024 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 12/6/2024 | Viatris | VTRS | Maintain | Neutral (N/A) |
|
Details | ||
| 12/5/2024 | Teva Pharma | TEVA | Maintain | Overweight (N/A) |
|
Details | ||
| 12/5/2024 | Alkermes | ALKS | Maintain | Overweight (N/A) |
|
Details | ||
| 11/21/2024 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 11/14/2024 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/13/2024 | Optinose | OPTN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/11/2024 | Amneal Pharmaceuticals | AMRX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/11/2024 | Xeris Pharmaceuticals | XERS | Downgrade | Neutral (Overweight) |
3.36 (5.81) |
72.92% | Details | |
| 11/7/2024 | Pacira Pharmaceuticals | PCRX | Maintain | Neutral (N/A) |
|
Details | ||
| 10/25/2024 | Alkermes | ALKS | Maintain | Overweight (N/A) |
|
Details | ||
| 10/25/2024 | Indivior | INDV | Maintain | Overweight (N/A) |
|
Details | ||
| 10/18/2024 | Supernus Pharmaceuticals | SUPN | Maintain | Neutral (N/A) |
|
Details | ||
| 10/14/2024 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2024 | Collegium Pharmaceutical | COLL | Maintain | Neutral (N/A) |
|
Details | ||
| 10/11/2024 | Indivior | INDV | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2024 | ANI Pharmaceuticals | ANIP | New Coverage | Overweight (N/A) |
56.73 (74.04) |
30.51% | Details | |
| 10/10/2024 | Alkermes | ALKS | Maintain | Overweight (N/A) |
|
Details | ||
| 10/2/2024 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Overweight (N/A) |
|
Details | ||
| 9/26/2024 | Viatris | VTRS | Maintain | Neutral (N/A) |
|
Details | ||
| 9/26/2024 | Alkermes | ALKS | Maintain | Overweight (N/A) |
|
Details | ||
| 9/13/2024 | Indivior | INDV | Maintain | Overweight (N/A) |
|
Details | ||
| 9/10/2024 | Supernus Pharmaceuticals | SUPN | Downgrade | Neutral (Overweight) |
33.91 (48.07) |
41.76% | Details | |
| 9/6/2024 | Intra-Cellular Therapies | ITCI | Upgrade | Overweight (Neutral) |
72.66 (94.87) |
30.57% | Details | |
| 8/29/2024 | Neurocrine Bio. | NBIX | Upgrade | Overweight (Neutral) |
152.55 (128.13) |
-16.01% | Details | |
| 8/28/2024 | Teva Pharma | TEVA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/12/2024 | Revance Therapeutic | rvnc | Downgrade | Neutral (Overweight) |
3.53 (3.65) |
3.4% | Details | |
| 8/12/2024 | Pacira Pharmaceuticals | PCRX | Downgrade | Neutral (Overweight) |
22.36 (22.00) |
-1.61% | Details | |
| 8/9/2024 | Collegium Pharmaceutical | COLL | Maintain | Neutral (N/A) |
|
Details | ||
| 8/8/2024 | Amphastar Pharmaceuticals | AMPH | Maintain | Overweight (N/A) |
|
Details | ||
| 8/2/2024 | Bausch Health Companies | BHC | Downgrade | Underweight (Neutral) |
6.03 (5.38) |
-10.78% | Details | |
| 8/1/2024 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 7/30/2024 | Corcept Therapeutics | CORT | Maintain | Overweight (N/A) |
|
Details | ||
| 7/23/2024 | Indivior | INDV | New Coverage | Overweight (N/A) |
10.41 (32.27) |
209.99% | Details | |
| 7/17/2024 | Corcept Therapeutics | CORT | Maintain | Overweight (N/A) |
|
Details | ||
| 7/15/2024 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Overweight (N/A) |
|
Details | ||
| 7/12/2024 | Teva Pharma | TEVA | Maintain | Overweight (N/A) |
|
Details | ||
| 7/3/2024 | Pacira Pharmaceuticals | PCRX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/1/2024 | Corcept Therapeutics | CORT | Maintain | Overweight (N/A) |
|
Details | ||
| 6/27/2024 | Amphastar Pharmaceuticals | AMPH | Maintain | Overweight (N/A) |
|
Details | ||
| 6/13/2024 | Teva Pharma | TEVA | Maintain | Overweight (N/A) |
|
Details | ||
| 6/10/2024 | Corcept Therapeutics | CORT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/28/2024 | Axsome Therapeutics | AXSM | Maintain | Overweight (N/A) |
|
Details | ||
| 5/24/2024 | Supernus Pharmaceuticals | SUPN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/23/2024 | Amphastar Pharmaceuticals | AMPH | Maintain | Overweight (N/A) |
|
Details | ||
| 5/22/2024 | Ironwood Pharmaceuticals | IRWD | Maintain | Overweight (N/A) |
|
Details | ||
| 5/21/2024 | Pacira Pharmaceuticals | PCRX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/13/2024 | Teva Pharma | TEVA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2024 | Xeris Pharmaceuticals | XERS | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2024 | Revance Therapeutic | RVNC | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2024 | Collegium Pharmaceutical | COLL | Downgrade | Neutral (Overweight) |
38.06 (37.29) |
-2.02% | Details | |
| 4/29/2024 | Organon & Co. | OGN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/29/2024 | Bausch Health Companies | BHC | Maintain | Neutral (N/A) |
|
Details | ||
| 4/11/2024 | Aquestive Therapeutics | AQST | New Coverage | Overweight (N/A) |
4.09 (4.22) |
3.18% | Details | |
| 3/28/2024 | Viatris | VTRS | Maintain | Neutral (N/A) |
|
Details | ||
| 3/21/2024 | Amneal Pharmaceuticals | AMRX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/20/2024 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 3/4/2024 | Avadel Pharmaceuticals | AVDL | Maintain | Overweight (N/A) |
|
Details | ||
| 2/29/2024 | Revance Therapeutic | RVNC | Maintain | Overweight (N/A) |
|
Details | ||
| 2/23/2024 | Collegium Pharmaceutical | COLL | Maintain | Overweight (N/A) |
|
Details | ||
| 2/16/2024 | Alkermes | ALKS | Maintain | Overweight (N/A) |
|
Details | ||
| 2/12/2024 | Teva Pharma | TEVA | Upgrade | Overweight (Neutral) |
12.09 (31.05) |
156.82% | Details | |
| 2/8/2024 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 1/3/2024 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 1/2/2024 | Teva Pharma | TEVA | Upgrade | Neutral (Underweight) |
10.44 (31.05) |
197.41% | Details | |
| 12/22/2023 | Karuna Therapeutics Inc. | KRTX | Downgrade | Neutral (Overweight) |
215.19 (329.83) |
53.27% | Details | |
| 12/7/2023 | Cerevel Therapeutics | CERE | Downgrade | Neutral (Overweight) |
35.59 (44.96) |
26.33% | Details | |
| 11/22/2023 | Viatris | VTRS | Maintain | Neutral (N/A) |
|
Details | ||
| 11/22/2023 | Organon & Co. | OGN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/14/2023 | Cara Therapeutics | CARA | Downgrade | Neutral (Overweight) |
1.05 (5.32) |
406.67% | Details | |
| 11/10/2023 | Xeris Pharmaceuticals | XERS | Maintain | Overweight (N/A) |
|
Details | ||
| 11/9/2023 | Supernus Pharmaceuticals | SUPN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/9/2023 | Revance Therapeutic | RVNC | Maintain | Overweight (N/A) |
|
Details | ||
| 11/3/2023 | Pacira Pharmaceuticals | PCRX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/1/2023 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 10/26/2023 | Alkermes | ALKS | Maintain | Overweight (N/A) |
|
Details | ||
| 10/25/2023 | Supernus Pharmaceuticals | SUPN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/25/2023 | Organon & Co. | OGN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/18/2023 | Corcept Therapeutics | CORT | Maintain | Overweight (N/A) |
|
Details | ||
| 9/28/2023 | Cerevel Therapeutics | CERE | New Coverage | Overweight (N/A) |
20.56 (44.96) |
118.68% | Details | |
| 9/20/2023 | Revance Therapeutic | RVNC | Maintain | Overweight (N/A) |
|
Details | ||
| 8/9/2023 | Eagle Pharmaceuticals | EGRX | Downgrade | Underweight (Neutral) |
22.88 (2.14) |
-90.65% | Details | |
| 8/9/2023 | Amphastar Pharmaceuticals | AMPH | Maintain | Overweight (N/A) |
|
Details | ||
| 8/8/2023 | Cara Therapeutics | CARA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/8/2023 | Axsome Therapeutics | AXSM | Upgrade | Overweight (Neutral) |
73.66 (162.33) |
120.38% | Details | |
| 8/7/2023 | Amneal Pharmaceuticals | AMRX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/15/2023 | Amphastar Pharmaceuticals | AMPH | Maintain | Overweight (N/A) |
|
Details | ||
| 6/7/2023 | Alkermes | ALKS | Maintain | Overweight (N/A) |
|
Details | ||
| 5/8/2023 | Amneal Pharmaceuticals | AMRX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/4/2023 | Corcept Therapeutics | CORT | New Coverage | Overweight (N/A) |
21.66 (33.87) |
56.37% | Details | |
| 3/21/2023 | Supernus Pharmaceuticals | SUPN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/7/2023 | Cara Therapeutics | CARA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/1/2023 | Amphastar Pharmaceuticals | AMPH | Maintain | Overweight (N/A) |
|
Details | ||
| 3/1/2023 | Revance Therapeutic | RVNC | Maintain | Overweight (N/A) |
|
Details | ||
| 3/1/2023 | Supernus Pharmaceuticals | SUPN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/17/2023 | Alkermes | ALKS | Maintain | Overweight (N/A) |
|
Details | ||
| 2/13/2023 | Collegium Pharmaceutical | COLL | Maintain | Overweight (N/A) |
|
Details | ||
| 2/9/2023 | Teva Pharma | TEVA | Maintain | Underweight (N/A) |
|
Details | ||
| 2/6/2023 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 1/31/2023 | Revance Therapeutic | RVNC | Maintain | Overweight (N/A) |
|
Details | ||
| 1/23/2023 | Supernus Pharmaceuticals | SUPN | Maintain | Overweight (N/A) |
|
Details | ||
| 1/5/2023 | Axsome Therapeutics | AXSM | New Coverage | Neutral (N/A) |
73.32 (162.33) |
121.4% | Details | |
| 1/5/2023 | Karuna Therapeutics Inc. | KRTX | New Coverage | Overweight (N/A) |
193.19 (329.83) |
70.73% | Details | |
| 1/4/2023 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Overweight (N/A) |
|
Details | ||
| 12/12/2022 | Horizon Therapeutics | HZNP | Downgrade | Neutral (Overweight) |
97.29 (116.30) |
19.54% | Details | |
| 12/7/2022 | Horizon Therapeutics | HZNP | Maintain | Overweight (N/A) |
|
Details | ||
| 11/23/2022 | Teva Pharma | TEVA | Maintain | Underweight (N/A) |
|
Details | ||
| 11/10/2022 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 11/9/2022 | Supernus Pharmaceuticals | SUPN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/8/2022 | Cara Therapeutics | CARA | Maintain | (N/A) |
|
Details | ||
| 11/8/2022 | Viatris | VTRS | Upgrade | Neutral (Underweight) |
9.70 (14.16) |
45.98% | Details | |
| 11/4/2022 | Pacira Pharmaceuticals | PCRX | Maintain | (N/A) |
|
Details | ||
| 11/4/2022 | Collegium Pharmaceutical | COLL | Maintain | (N/A) |
|
Details | ||
| 11/3/2022 | Alkermes | ALKS | Upgrade | Overweight (Neutral) |
24.06 (28.63) |
18.99% | Details | |
| 11/2/2022 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 11/1/2022 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Overweight (N/A) |
|
Details | ||
| 10/25/2022 | Horizon Therapeutics | HZNP | Maintain | Overweight (N/A) |
|
Details | ||
| 10/25/2022 | Amphastar Pharmaceuticals | AMPH | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2022 | Supernus Pharmaceuticals | SUPN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/9/2022 | Bausch Health Companies | BHC | Maintain | Neutral (N/A) |
|
Details | ||
| 9/6/2022 | Organon & Co. | OGN | Upgrade | Overweight (Neutral) |
28.81 (9.16) |
-68.21% | Details | |
| 8/31/2022 | Supernus Pharmaceuticals | SUPN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/16/2022 | Alkermes | ALKS | New Coverage | Neutral (N/A) |
26.15 (28.63) |
9.48% | Details | |
| 8/12/2022 | Optinose | OPTN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/10/2022 | Eagle Pharmaceuticals | EGRX | Maintain | Neutral (N/A) |
|
Details | ||
| 8/9/2022 | Amphastar Pharmaceuticals | AMPH | Maintain | Overweight (N/A) |
|
Details | ||
| 8/4/2022 | Pacira Pharmaceuticals | PCRX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/29/2022 | Teva Pharma | TEVA | Maintain | Underweight (N/A) |
|
Details | ||
| 7/21/2022 | Pacira Pharmaceuticals | PCRX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/25/2022 | Evofem Biosciences Inc | EVFM | Maintain | Overweight (N/A) |
|
Details | ||
| 5/11/2022 | Collegium Pharmaceutical | COLL | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2022 | Supernus Pharmaceuticals | SUPN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2022 | Eagle Pharmaceuticals | EGRX | Maintain | Neutral (N/A) |
|
Details | ||
| 5/10/2022 | Amphastar Pharmaceuticals | AMPH | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2022 | Viatris | VTRS | Downgrade | Underweight (Neutral) |
9.95 (14.16) |
42.31% | Details | |
| 5/6/2022 | Endo International plc | ENDP | Downgrade | Underweight (Neutral) |
2.02 (0.29) |
-85.64% | Details | |
| 5/5/2022 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 5/5/2022 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 5/4/2022 | Teva Pharma | TEVA | Downgrade | Underweight (Neutral) |
8.60 (31.05) |
261.05% | Details | |
| 4/29/2022 | Collegium Pharmaceutical | COLL | Maintain | Overweight (N/A) |
|
Details | ||
| 4/14/2022 | Antares Pharma | ATRS | Downgrade | Neutral (Overweight) |
3.74 (5.59) |
49.47% | Details | |
| 4/8/2022 | Amphastar Pharmaceuticals | AMPH | Maintain | Overweight (N/A) |
|
Details | ||
| 3/16/2022 | Viatris | VTRS | Maintain | Neutral (N/A) |
|
Details | ||
| 3/11/2022 | Amphastar Pharmaceuticals | AMPH | Maintain | Overweight (N/A) |
|
Details | ||
| 3/3/2022 | Neurocrine Bio. | NBIX | Downgrade | Neutral (Overweight) |
91.86 (152.55) |
66.07% | Details | |
| 3/2/2022 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 3/2/2022 | Endo International plc | ENDP | Maintain | Neutral (N/A) |
|
Details | ||
| 3/1/2022 | Supernus Pharmaceuticals | SUPN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/24/2022 | Bausch Health Companies | BHC | Maintain | Neutral (N/A) |
|
Details | ||
| 2/22/2022 | Collegium Pharmaceutical | COLL | Maintain | Overweight (N/A) |
|
Details | ||
| 2/17/2022 | Organon & Co. | OGN | Maintain | Neutral (N/A) |
|
Details | ||
| 2/15/2022 | BioDelivery Sciences International | BDSI | Downgrade | Neutral (Overweight) |
3.64 (5.59) |
53.57% | Details | |
| 2/14/2022 | Horizon Therapeutics | HZNP | Maintain | Overweight (N/A) |
|
Details | ||
| 2/2/2022 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Overweight (N/A) |
|
Details | ||
| 1/26/2022 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/26/2022 | Horizon Therapeutics | HZNP | Maintain | Overweight (N/A) |
|
Details | ||
| 1/7/2022 | Amphastar Pharmaceuticals | AMPH | Upgrade | Overweight (Neutral) |
23.08 (34.87) |
51.08% | Details | |
| 12/15/2021 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 11/19/2021 | Optinose | OPTN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/16/2021 | Evofem Biosciences Inc | EVFM | Maintain | Overweight (N/A) |
|
Details | ||
| 11/10/2021 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 11/10/2021 | Revance Therapeutic | RVNC | Maintain | Overweight (N/A) |
|
Details | ||
| 11/9/2021 | Viatris | VTRS | Maintain | Neutral (N/A) |
|
Details | ||
| 11/9/2021 | Amphastar Pharmaceuticals | AMPH | Maintain | Neutral (N/A) |
|
Details | ||
| 11/4/2021 | Supernus Pharmaceuticals | SUPN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/4/2021 | BioDelivery Sciences International | BDSI | Maintain | Overweight (N/A) |
|
Details | ||
| 11/3/2021 | Horizon Therapeutics | HZNP | Maintain | Overweight (N/A) |
|
Details | ||
| 11/2/2021 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/18/2021 | Revance Therapeutic | RVNC | Maintain | Overweight (N/A) |
|
Details | ||
| 10/13/2021 | Horizon Therapeutics | HZNP | Maintain | Overweight (N/A) |
|
Details | ||
| 10/12/2021 | Adamas Pharmaceuticals | ADMS | Downgrade | Neutral (Overweight) |
4.61 (8.22) |
78.31% | Details | |
| 10/7/2021 | Organon & Co. | OGN | New Coverage | Neutral (N/A) |
32.53 (6.56) |
-79.83% | Details | |
| 9/28/2021 | Cara Therapeutics | CARA | Maintain | Overweight (N/A) |
|
Details | ||
| 9/15/2021 | Revance Therapeutic | RVNC | Maintain | Overweight (N/A) |
|
Details | ||
| 9/1/2021 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 8/31/2021 | Endo International plc | ENDP | Downgrade | Neutral (Overweight) |
2.30 (0.29) |
-87.39% | Details | |
| 8/16/2021 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/13/2021 | VYNE Therapeutics | VYNE | Maintain | (Overweight) |
|
Details | ||
| 8/4/2021 | Horizon Therapeutics | HZNP | Maintain | Overweight (N/A) |
|
Details | ||
| 7/8/2021 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/23/2021 | Horizon Therapeutics | HZNP | Maintain | Overweight (N/A) |
|
Details | ||
| 6/18/2021 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Overweight (N/A) |
|
Details | ||
| 6/15/2021 | Xeris Pharmaceuticals | XERS | Maintain | Overweight (N/A) |
|
Details | ||
| 5/24/2021 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 5/11/2021 | Revance Therapeutic | RVNC | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2021 | Collegium Pharmaceutical | COLL | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2021 | Evofem Biosciences Inc | EVFM | Maintain | Overweight (N/A) |
|
Details | ||
| 5/6/2021 | Baudax Bio Inc. | BXRX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/6/2021 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/27/2021 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 4/19/2021 | Endo International plc | ENDP | Maintain | Overweight (N/A) |
|
Details | ||
| 4/6/2021 | Cara Therapeutics | CARA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/3/2021 | Eagle Pharmaceuticals | EGRX | Maintain | Neutral (N/A) |
|
Details | ||
| 2/25/2021 | Bausch Health Companies | BHC | Maintain | Neutral (N/A) |
|
Details | ||
| 2/24/2021 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 2/10/2021 | Baudax Bio Inc. | BXRX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/10/2021 | Antares Pharma | ATRS | Maintain | Overweight (N/A) |
|
Details | ||
| 2/10/2021 | Adamas Pharmaceuticals | ADMS | Maintain | Overweight (N/A) |
|
Details | ||
| 2/10/2021 | Revance Therapeutic | RVNC | Maintain | Overweight (N/A) |
|
Details | ||
| 2/10/2021 | Collegium Pharmaceutical | COLL | Maintain | Overweight (N/A) |
|
Details | ||
| 2/5/2021 | Horizon Therapeutics | HZNP | Maintain | Overweight (N/A) |
|
Details | ||
| 2/3/2021 | Jazz Pharmaceuticals | JAZZ | Upgrade | Overweight (Neutral) |
157.29 (182.01) |
15.72% | Details | |
| 1/20/2021 | Pacira Pharmaceuticals | PCRX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/4/2021 | Endo International plc | ENDP | Maintain | Overweight (N/A) |
|
Details | ||
| 11/6/2020 | Collegium Pharmaceutical | COLL | Maintain | Overweight (N/A) |
|
Details | ||
| 11/5/2020 | Bausch Health Companies | BHC | Maintain | Overweight (N/A) |
|
Details | ||
| 10/9/2020 | Amneal Pharmaceuticals | AMRX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/9/2020 | Endo International plc | ENDP | Maintain | Overweight (N/A) |
|
Details | ||
| 9/29/2020 | Xeris Pharmaceuticals | XERS | Maintain | Overweight (N/A) |
|
Details | ||
| 9/14/2020 | Harmony Biosciences Holdings Inc. | HRMY | New Coverage | Overweight (N/A) |
44.39 (28.33) |
-36.18% | Details | |
| 8/19/2020 | Bausch Health Companies | BHC | Maintain | Overweight (N/A) |
|
Details | ||
| 8/4/2020 | Mallinckrodt plc | MNK | Downgrade | Underweight (Neutral) |
2.26 (0.34) |
-84.96% | Details | |
| 8/4/2020 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/22/2020 | Horizon Therapeutics | HZNP | Maintain | Overweight (N/A) |
|
Details | ||
| 6/16/2020 | Supernus Pharmaceuticals | SUPN | Upgrade | Overweight (Neutral) |
22.83 (33.91) |
48.53% | Details | |
| 6/8/2020 | Evofem Biosciences Inc | EVFM | New Coverage | Overweight (N/A) |
3.31 (0.01) |
-99.7% | Details | |
| 6/5/2020 | Horizon Therapeutics | HZNP | Maintain | Overweight (N/A) |
|
Details | ||
| 6/1/2020 | Neurocrine Bio. | NBIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/21/2020 | Horizon Therapeutics | HZNP | Maintain | Overweight (N/A) |
|
Details | ||
| 5/15/2020 | Teva Pharma | TEVA | Maintain | Neutral (N/A) |
|
Details | ||
| 5/6/2020 | Jazz Pharmaceuticals | JAZZ | Maintain | Neutral (N/A) |
|
Details | ||
| 5/4/2020 | Avadel Pharmaceuticals | AVDL | Maintain | Overweight (N/A) |
|
Details | ||
| 3/9/2020 | Mallinckrodt plc | MNK | Maintain | Neutral (N/A) |
|
Details | ||
| 3/3/2020 | Eagle Pharmaceuticals | EGRX | Maintain | Neutral (N/A) |
|
Details | ||
| 2/28/2020 | Mylan | MYL | Maintain | Neutral (N/A) |
|
Details | ||
| 2/28/2020 | Collegium Pharmaceutical | COLL | Maintain | Overweight (N/A) |
|
Details | ||
| 2/27/2020 | Supernus Pharmaceuticals | SUPN | Maintain | Neutral (N/A) |
|
Details | ||
| 2/26/2020 | Jazz Pharmaceuticals | JAZZ | Maintain | Neutral (N/A) |
|
Details | ||
| 2/26/2020 | Avadel Pharmaceuticals | AVDL | New Coverage | Overweight (N/A) |
10.64 (21.64) |
103.38% | Details | |
| 2/25/2020 | Revance Therapeutic | RVNC | Maintain | Overweight (N/A) |
|
Details | ||
| 2/21/2020 | Baudax Bio Inc. | BXRX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/20/2020 | Pacira Pharmaceuticals | PCRX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/20/2020 | Bausch Health Companies | BHC | Maintain | Overweight (N/A) |
|
Details | ||
| 2/18/2020 | Revance Therapeutic | RVNC | Maintain | Overweight (N/A) |
|
Details | ||
| 2/18/2020 | Xeris Pharmaceuticals | XERS | New Coverage | Overweight (N/A) |
4.13 (3.36) |
-18.64% | Details | |
| 2/14/2020 | Baudax Bio Inc. | BXRX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/13/2020 | Teva Pharma | TEVA | Maintain | Neutral (N/A) |
|
Details | ||
| 2/12/2020 | Collegium Pharmaceutical | COLL | Maintain | Overweight (N/A) |
|
Details | ||
| 2/5/2020 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/9/2020 | Mylan | MYL | New Coverage | Neutral (N/A) |
21.17 (15.86) |
-25.08% | Details | |
| 1/9/2020 | BioDelivery Sciences International | BDSI | New Coverage | Overweight (N/A) |
5.71 (5.59) |
-2.1% | Details | |
| 1/6/2020 | Novan | NOVN | Downgrade | Neutral (Overweight) |
3.11 (0.09) |
-97.11% | Details | |
| 1/3/2020 | Endo International plc | ENDP | Upgrade | Overweight (Neutral) |
4.69 (2.30) |
-50.96% | Details | |
| 12/30/2019 | Bausch Health Companies | BHC | Maintain | Overweight (N/A) |
|
Details | ||
| 12/17/2019 | Adamas Pharmaceuticals | ADMS | Maintain | Overweight (N/A) |
|
Details | ||
| 12/13/2019 | Amneal Pharmaceuticals | AMRX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/12/2019 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/9/2019 | Revance Therapeutic | RVNC | Maintain | Overweight (N/A) |
|
Details | ||
| 11/22/2019 | Baudax Bio Inc. | BXRX | New Coverage | Overweight (N/A) |
0.00 (0.19) |
0% | Details | |
| 11/13/2019 | Optinose | OPTN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/8/2019 | Teva Pharma | TEVA | Maintain | Neutral (N/A) |
|
Details | ||
| 11/8/2019 | Amphastar Pharmaceuticals | AMPH | Maintain | Neutral (N/A) |
|
Details | ||
| 11/8/2019 | Adamas Pharmaceuticals | ADMS | Maintain | Overweight (N/A) |
|
Details | ||
| 11/7/2019 | Collegium Pharmaceutical | COLL | Maintain | Overweight (N/A) |
|
Details | ||
| 11/7/2019 | Amneal Pharmaceuticals | AMRX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/5/2019 | Revance Therapeutic | RVNC | Maintain | Overweight (N/A) |
|
Details | ||
| 11/5/2019 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/21/2019 | Jazz Pharmaceuticals | JAZZ | Downgrade | Neutral (Overweight) |
136.45 (157.29) |
15.27% | Details | |
| 8/13/2019 | Optinose | OPTN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/9/2019 | Recro Pharma | REPH | Maintain | Overweight (N/A) |
|
Details | ||
| 8/9/2019 | Adamas Pharmaceuticals | ADMS | Maintain | Overweight (N/A) |
|
Details | ||
| 8/7/2019 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 8/7/2019 | Allergen | AGN | Maintain | Neutral (N/A) |
|
Details | ||
| 8/6/2019 | Revance Therapeutic | RVNC | Maintain | Overweight (N/A) |
|
Details | ||
| 7/30/2019 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/30/2019 | Cara Therapeutics | CARA | Maintain | Overweight (N/A) |
|
Details | ||
| 7/8/2019 | Amneal Pharmaceuticals | AMRX | Upgrade | Overweight (Neutral) |
6.97 (13.24) |
89.96% | Details | |
| 5/31/2019 | Mallinckrodt plc | MNK | Downgrade | Neutral (Overweight) |
9.30 (2.26) |
-75.7% | Details | |
| 5/7/2019 | Akorn | AKRX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/2/2019 | Pacira Pharmaceuticals | PCRX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/30/2019 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/29/2019 | Endo International plc | ENDP | Maintain | Neutral (N/A) |
|
Details | ||
| 4/9/2019 | Pacira Pharmaceuticals | PCRX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/4/2019 | Horizon Pharma | HZNP | Maintain | Overweight (N/A) |
|
Details | ||
| 3/13/2019 | Cara Therapeutics | CARA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/13/2019 | Amphastar Pharmaceuticals | AMPH | Downgrade | Neutral (Overweight) |
23.72 (19.34) |
-18.47% | Details | |
| 3/5/2019 | Adamas Pharmaceuticals | ADMS | Maintain | Overweight (N/A) |
|
Details | ||
| 3/5/2019 | Adamas Pharmaceuticals | ADMS | Maintain | Overweight (N/A) |
|
Details | ||
| 3/1/2019 | Endo International plc | ENDP | Maintain | Neutral (N/A) |
|
Details | ||
| 3/1/2019 | Amneal Pharmaceuticals | AMRX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/1/2019 | Akorn | AKRX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/27/2019 | Mallinckrodt plc | MNK | Maintain | Overweight (N/A) |
|
Details | ||
| 2/27/2019 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 2/6/2019 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/30/2019 | Allergen | AGN | Maintain | Neutral (N/A) |
|
Details | ||
| 1/23/2019 | Teva Pharma | TEVA | Upgrade | Neutral (Underweight) |
18.82 (31.05) |
64.98% | Details | |
| 1/14/2019 | Horizon Pharma | HZNP | Maintain | Overweight (N/A) |
|
Details | ||
| 1/2/2019 | Bausch Health Companies | BHC | Upgrade | Overweight (Neutral) |
18.47 (6.03) |
-67.35% | Details | |
| 11/8/2018 | Recro Pharma | REPH | Maintain | Overweight (N/A) |
|
Details | ||
| 11/7/2018 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 11/6/2018 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/1/2018 | Pacira Pharmaceuticals | PCRX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/31/2018 | Eagle Pharmaceuticals | EGRX | Downgrade | Neutral (Overweight) |
56.90 (2.14) |
-96.24% | Details | |
| 10/24/2018 | Amneal Pharmaceuticals | AMRX | Maintain | Neutral (N/A) |
|
Details | ||
| 10/19/2018 | Jazz Pharmaceuticals | JAZZ | Maintain | Overweight (N/A) |
|
Details | ||
| 10/17/2018 | Akorn | AKRX | Upgrade | Overweight (Neutral) |
6.26 (0.09) |
-98.56% | Details | |
| 10/9/2018 | Pacira Pharmaceuticals | PCRX | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/2/2018 | Akorn | AKRX | Maintain | Neutral (N/A) |
|
Details | ||
| 9/17/2018 | Teva Pharma | TEVA | Maintain | Underweight (Underweight) |
|
Details | ||
| 9/17/2018 | Allergen | AGN | Maintain | Neutral (N/A) |
|
Details | ||
| 9/17/2018 | Revance Therapeutic | RVNC | Maintain | Overweight (N/A) |
|
Details | ||
| 9/17/2018 | Horizon Pharma | HZNP | Maintain | Overweight (N/A) |
|
Details | ||
| 9/13/2018 | Bausch Health Companies | BHC | Upgrade | Neutral (Underweight) |
23.54 (18.47) |
-21.54% | Details | |
| 8/17/2018 | Antares Pharma | ATRS | Maintain | Overweight (N/A) |
|
Details | ||
| 8/14/2018 | Optinose | OPTN | Maintain | Overweight (N/A) |
|
Details |
